What is the current valuation of the Americas Insomnia Market?

The Americas Insomnia Market was valued at 2.43 USD Billion in 2024. Read More

What is the projected market size for the Americas Insomnia Market by 2035?

The market is projected to reach 4.122 USD Billion by 2035. Read More

What is the expected CAGR for the Americas Insomnia Market during the forecast period?

The expected CAGR for the Americas Insomnia Market from 2025 to 2035 is 4.92%. Read More

Which companies are the key players in the Americas Insomnia Market?

Key players include Pfizer Inc, Merck & Co Inc, Eli Lilly and Company, and others. Read More

What are the main segments of the Americas Insomnia Market?

The main segments include Pharmacological Therapy and Non-Pharmacological Therapy. Read More

How did the Pharmacological Therapy segment perform in 2024?

In 2024, the Pharmacological Therapy segment was valued at 2.5 USD Billion. Read More

What is the projected growth for Non-Pharmacological Therapy by 2035?

The Non-Pharmacological Therapy segment is expected to grow to 1.62 USD Billion by 2035. Read More

What are the leading drug formulations in the Americas Insomnia Market?

Leading drug formulations include Capsules, Tablets, and others, with Tablets valued at 1.85 USD Billion by 2035. Read More

What types of diseases are primarily addressed in the Americas Insomnia Market?

The market addresses issues such as poor quality of sleep and sleep maintenance. Read More

What is the expected performance of the Benzodiazepines segment by 2035?

The Benzodiazepines segment is projected to reach 1.3 USD Billion by 2035. Read More

Americas Insomnia Market

ID: MRFR/Pharma/0126-HCR

50 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Americas Insomnia Market Research Report, by types of therapy (Pharmacological therapy and Non Pharmacological therapy), by drug formulation (Capsules, Tablet and others), by type of disease (poor quality of sleep, sleep maintenance and others) - Forecast till 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type of Therapy (USD Billion)
4.1.1 Pharmacological Therapy
4.1.2 Non-Pharmacological Therapy
4.2 Healthcare, BY Pharmacological Therapy (USD Billion)
4.2.1 Benzodiazepines
4.2.2 Non-benzodiazepines
4.2.3 Melatonin receptor agonists
4.2.4 Others
4.3 Healthcare, BY Non-Pharmacological Therapy (USD Billion)
4.3.1 Relaxation therapy
4.3.2 Cognitive behavioural therapy
4.3.3 Sleep hygiene education
4.3.4 Stimulus Controls
4.3.5 Paradoxical intention
4.3.6 Others
4.4 Healthcare, BY Drug Formulation (USD Billion)
4.4.1 Capsules
4.4.2 Tablets
4.4.3 Others
4.5 Healthcare, BY Type of Disease (USD Billion)
4.5.1 Poor quality of sleep
4.5.2 Sleep maintenance
4.5.3 Others
4.6 Healthcare, BY Region (USD Billion)
4.6.1 North America
4.6.1.1 US
4.6.1.2 Canada
4.6.2 Europe
4.6.2.1 Germany
4.6.2.2 UK
4.6.2.3 France
4.6.2.4 Russia
4.6.2.5 Italy
4.6.2.6 Spain
4.6.2.7 Rest of Europe
4.6.3 APAC
4.6.3.1 China
4.6.3.2 India
4.6.3.3 Japan
4.6.3.4 South Korea
4.6.3.5 Malaysia
4.6.3.6 Thailand
4.6.3.7 Indonesia
4.6.3.8 Rest of APAC
4.6.4 South America
4.6.4.1 Brazil
4.6.4.2 Mexico
4.6.4.3 Argentina
4.6.4.4 Rest of South America
4.6.5 MEA
4.6.5.1 GCC Countries
4.6.5.2 South Africa
4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Pfizer Inc (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Merck & Co Inc (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Eli Lilly and Company (US)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Teva Pharmaceutical Industries Ltd (IL)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 AstraZeneca PLC (GB)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Sanofi S.A. (FR)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Bristol-Myers Squibb Company (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Johnson & Johnson (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Novartis AG (CH)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE OF THERAPY
6.4 US MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.5 US MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.6 US MARKET ANALYSIS BY DRUG FORMULATION
6.7 US MARKET ANALYSIS BY TYPE OF DISEASE
6.8 CANADA MARKET ANALYSIS BY TYPE OF THERAPY
6.9 CANADA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.10 CANADA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.11 CANADA MARKET ANALYSIS BY DRUG FORMULATION
6.12 CANADA MARKET ANALYSIS BY TYPE OF DISEASE
6.13 EUROPE MARKET ANALYSIS
6.14 GERMANY MARKET ANALYSIS BY TYPE OF THERAPY
6.15 GERMANY MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.16 GERMANY MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.17 GERMANY MARKET ANALYSIS BY DRUG FORMULATION
6.18 GERMANY MARKET ANALYSIS BY TYPE OF DISEASE
6.19 UK MARKET ANALYSIS BY TYPE OF THERAPY
6.20 UK MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.21 UK MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.22 UK MARKET ANALYSIS BY DRUG FORMULATION
6.23 UK MARKET ANALYSIS BY TYPE OF DISEASE
6.24 FRANCE MARKET ANALYSIS BY TYPE OF THERAPY
6.25 FRANCE MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.26 FRANCE MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.27 FRANCE MARKET ANALYSIS BY DRUG FORMULATION
6.28 FRANCE MARKET ANALYSIS BY TYPE OF DISEASE
6.29 RUSSIA MARKET ANALYSIS BY TYPE OF THERAPY
6.30 RUSSIA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.31 RUSSIA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.32 RUSSIA MARKET ANALYSIS BY DRUG FORMULATION
6.33 RUSSIA MARKET ANALYSIS BY TYPE OF DISEASE
6.34 ITALY MARKET ANALYSIS BY TYPE OF THERAPY
6.35 ITALY MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.36 ITALY MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.37 ITALY MARKET ANALYSIS BY DRUG FORMULATION
6.38 ITALY MARKET ANALYSIS BY TYPE OF DISEASE
6.39 SPAIN MARKET ANALYSIS BY TYPE OF THERAPY
6.40 SPAIN MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.41 SPAIN MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.42 SPAIN MARKET ANALYSIS BY DRUG FORMULATION
6.43 SPAIN MARKET ANALYSIS BY TYPE OF DISEASE
6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE OF THERAPY
6.45 REST OF EUROPE MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.46 REST OF EUROPE MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.47 REST OF EUROPE MARKET ANALYSIS BY DRUG FORMULATION
6.48 REST OF EUROPE MARKET ANALYSIS BY TYPE OF DISEASE
6.49 APAC MARKET ANALYSIS
6.50 CHINA MARKET ANALYSIS BY TYPE OF THERAPY
6.51 CHINA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.52 CHINA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.53 CHINA MARKET ANALYSIS BY DRUG FORMULATION
6.54 CHINA MARKET ANALYSIS BY TYPE OF DISEASE
6.55 INDIA MARKET ANALYSIS BY TYPE OF THERAPY
6.56 INDIA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.57 INDIA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.58 INDIA MARKET ANALYSIS BY DRUG FORMULATION
6.59 INDIA MARKET ANALYSIS BY TYPE OF DISEASE
6.60 JAPAN MARKET ANALYSIS BY TYPE OF THERAPY
6.61 JAPAN MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.62 JAPAN MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.63 JAPAN MARKET ANALYSIS BY DRUG FORMULATION
6.64 JAPAN MARKET ANALYSIS BY TYPE OF DISEASE
6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE OF THERAPY
6.66 SOUTH KOREA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.67 SOUTH KOREA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.68 SOUTH KOREA MARKET ANALYSIS BY DRUG FORMULATION
6.69 SOUTH KOREA MARKET ANALYSIS BY TYPE OF DISEASE
6.70 MALAYSIA MARKET ANALYSIS BY TYPE OF THERAPY
6.71 MALAYSIA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.72 MALAYSIA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.73 MALAYSIA MARKET ANALYSIS BY DRUG FORMULATION
6.74 MALAYSIA MARKET ANALYSIS BY TYPE OF DISEASE
6.75 THAILAND MARKET ANALYSIS BY TYPE OF THERAPY
6.76 THAILAND MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.77 THAILAND MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.78 THAILAND MARKET ANALYSIS BY DRUG FORMULATION
6.79 THAILAND MARKET ANALYSIS BY TYPE OF DISEASE
6.80 INDONESIA MARKET ANALYSIS BY TYPE OF THERAPY
6.81 INDONESIA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.82 INDONESIA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.83 INDONESIA MARKET ANALYSIS BY DRUG FORMULATION
6.84 INDONESIA MARKET ANALYSIS BY TYPE OF DISEASE
6.85 REST OF APAC MARKET ANALYSIS BY TYPE OF THERAPY
6.86 REST OF APAC MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.87 REST OF APAC MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.88 REST OF APAC MARKET ANALYSIS BY DRUG FORMULATION
6.89 REST OF APAC MARKET ANALYSIS BY TYPE OF DISEASE
6.90 SOUTH AMERICA MARKET ANALYSIS
6.91 BRAZIL MARKET ANALYSIS BY TYPE OF THERAPY
6.92 BRAZIL MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.93 BRAZIL MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.94 BRAZIL MARKET ANALYSIS BY DRUG FORMULATION
6.95 BRAZIL MARKET ANALYSIS BY TYPE OF DISEASE
6.96 MEXICO MARKET ANALYSIS BY TYPE OF THERAPY
6.97 MEXICO MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.98 MEXICO MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.99 MEXICO MARKET ANALYSIS BY DRUG FORMULATION
6.100 MEXICO MARKET ANALYSIS BY TYPE OF DISEASE
6.101 ARGENTINA MARKET ANALYSIS BY TYPE OF THERAPY
6.102 ARGENTINA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.103 ARGENTINA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.104 ARGENTINA MARKET ANALYSIS BY DRUG FORMULATION
6.105 ARGENTINA MARKET ANALYSIS BY TYPE OF DISEASE
6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF THERAPY
6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG FORMULATION
6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF DISEASE
6.111 MEA MARKET ANALYSIS
6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF THERAPY
6.113 GCC COUNTRIES MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.114 GCC COUNTRIES MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.115 GCC COUNTRIES MARKET ANALYSIS BY DRUG FORMULATION
6.116 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF DISEASE
6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF THERAPY
6.118 SOUTH AFRICA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.119 SOUTH AFRICA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.120 SOUTH AFRICA MARKET ANALYSIS BY DRUG FORMULATION
6.121 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF DISEASE
6.122 REST OF MEA MARKET ANALYSIS BY TYPE OF THERAPY
6.123 REST OF MEA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
6.124 REST OF MEA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6.125 REST OF MEA MARKET ANALYSIS BY DRUG FORMULATION
6.126 REST OF MEA MARKET ANALYSIS BY TYPE OF DISEASE
6.127 KEY BUYING CRITERIA OF HEALTHCARE
6.128 RESEARCH PROCESS OF MRFR
6.129 DRO ANALYSIS OF HEALTHCARE
6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
6.133 HEALTHCARE, BY TYPE OF THERAPY, 2024 (% SHARE)
6.134 HEALTHCARE, BY TYPE OF THERAPY, 2024 TO 2035 (USD Billion)
6.135 HEALTHCARE, BY PHARMACOLOGICAL THERAPY, 2024 (% SHARE)
6.136 HEALTHCARE, BY PHARMACOLOGICAL THERAPY, 2024 TO 2035 (USD Billion)
6.137 HEALTHCARE, BY NON-PHARMACOLOGICAL THERAPY, 2024 (% SHARE)
6.138 HEALTHCARE, BY NON-PHARMACOLOGICAL THERAPY, 2024 TO 2035 (USD Billion)
6.139 HEALTHCARE, BY DRUG FORMULATION, 2024 (% SHARE)
6.140 HEALTHCARE, BY DRUG FORMULATION, 2024 TO 2035 (USD Billion)
6.141 HEALTHCARE, BY TYPE OF DISEASE, 2024 (% SHARE)
6.142 HEALTHCARE, BY TYPE OF DISEASE, 2024 TO 2035 (USD Billion)
6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.2.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.2.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.2.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.2.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.3.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.3.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.3.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.3.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.4.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.4.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.4.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.4.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.5.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.5.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.5.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.5.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.6.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.6.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.6.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.6.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.7.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.7.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.7.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.7.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.8.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.8.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.8.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.8.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.9.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.9.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.9.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.9.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.10.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.10.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.10.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.10.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.11.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.11.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.11.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.11.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.12.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.12.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.12.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.12.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.13.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.13.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.13.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.13.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.14.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.14.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.14.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.14.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.15.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.15.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.15.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.15.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.16.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.16.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.16.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.16.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.17.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.17.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.17.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.17.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.18.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.18.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.18.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.18.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.19.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.19.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.19.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.19.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.20.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.20.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.20.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.20.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.21.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.21.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.21.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.21.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.22.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.22.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.22.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.22.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.23.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.23.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.23.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.23.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.24.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.24.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.24.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.24.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.25.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.25.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.25.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.25.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.26.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.26.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.26.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.26.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.27.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.27.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.27.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.27.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.28.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.28.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.28.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.28.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.29.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.29.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.29.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.29.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
7.30.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.30.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
7.30.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
7.30.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type of Therapy (USD Billion, 2025-2035)

Pharmacological Therapy
Non-Pharmacological Therapy

Healthcare By Pharmacological Therapy (USD Billion, 2025-2035)

Benzodiazepines
Non-benzodiazepines
Melatonin receptor agonists
Others

Healthcare By Non-Pharmacological Therapy (USD Billion, 2025-2035)

Relaxation therapy
Cognitive behavioural therapy
Sleep hygiene education
Stimulus Controls
Paradoxical intention
Others

Healthcare By Drug Formulation (USD Billion, 2025-2035)

Capsules
Tablets
Others

Healthcare By Type of Disease (USD Billion, 2025-2035)

Poor quality of sleep
Sleep maintenance
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓